Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 12, 2015, Pages 2079-2095

  Niesen, Judith ^a   Stein, Christoph ^a,b   Brehm, Hannes ^b   Hehmann Titt, Grit ^d   Fendel, Rolf ^a,b   Melmer, Georg ^d   Fischer, Rainer ^a,c   Barth, Stefan ^a,b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d PharmedArtis GmbH   (Germany)

Author keywords

Cancer therapy; Epidermal growth factor receptor (EGFR); Immunotoxin (IT); Pseudomonas exotoxin A (ETA ); Single chain fragment variable (scFv); SNAP tag

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; PANITUMUMAB; PSEUDOMONAS EXOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; EGFR PROTEIN, HUMAN; EXOTOXIN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RHABDOMYOSARCOMA; SOLID TUMOR; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADP RIBOSE TRANSFERASES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BACTERIAL TOXINS; BLOTTING, WESTERN; CELL PROLIFERATION; CETUXIMAB; EXOTOXINS; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 84946478687     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1975-5     Document Type: Article

References (84)

1. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M (2012) scFv antibody: principles and clinical application. Clin Dev Immunol 2012:980250. doi:10.1155/2012/980250
2. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750–763. doi:10.1038/nrc903
3. Alvarenga ML et al (2012) In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor. Anal Biochem 421:138–151. doi:10.1016/j.ab.2011.10.039
4. Amoury M et al (2013) SNAP-tag based agents for preclinical in vitro imaging in malignant diseases. Curr Pharm Des 19:5429–5436
5. Antignani A, Fitzgerald D (2013) Immunotoxins: the role of the toxin. Toxins 5:1486–1502. doi:10.3390/toxins5081486
6. Armistead PM et al (2007) Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 110:2293–2303. doi:10.1002/cncr.23038
7. Asano R et al (2013) Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers. FEBS J 280:4816–4826. doi:10.1111/febs.12451
8. Azemar M et al (2000) Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86:269–275
9. Bachran D et al (2010) Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells. Int J Cancer 127:1453–1461. doi:10.1002/ijc.25123
10. Barnea I, Ben-Yosef R, Karaush V, Benhar I, Vexler A (2013) Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: results of in vitro and in vivo studies. Head Neck 35:1171–1177. doi:10.1002/hed.23093
11. Barth S (2002) Technology evaluation: bL22, NCI. Curr opin Mol Ther 4:72–75
12. Becker N, Benhar I (2012) Antibody-based immunotoxins for the treatment of cancer. Antibodies 1:39–69. doi:10.3390/antib1010039
13. Bruell D et al (2003) The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA′ suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23:1179–1186
14. Bruell D et al (2005) Recombinant anti-EGFR immunotoxin 425(scFv)-ETA′ demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 15:305–313
15. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia (New York, NY) 1:50–62
16. Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG (2013) Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol Cancer Ther 12:979–991. doi:10.1158/1535-7163.MCT-13-0002
17. Carey LA et al (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30:2615–2623. doi:10.1200/JCO.2010.34.5579
18. Cathomas R et al (2012) Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 18:6049–6057. doi:10.1158/1078-0432.ccr-12-2219
19. Chandramohan V, Bigner DD (2013) A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. Oncoimmunology 2:e26852. doi:10.4161/onci.26852
20. Chandramohan V et al (2013) Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 19:4717–4727. doi:10.1158/1078-0432.ccr-12-3891
21. Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I (1987) Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci USA 84:4538–4542
22. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC (2009) Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother (Hagerstown, Md: 1997) 32:574–584. doi:10.1097/CJI.0b013e3181a6981c
23. de Goeij BE et al (2014) HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. mAbs 6:392–402. doi:10.4161/mabs.27705
24. de Larco JE, Todaro GJ (1978) Epithelioid and fibroblastic rat kidney cell clones: epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation. J Cell Physiol 94:335–342. doi:10.1002/jcp.1040940311
25. Faller BA, Burtness B (2009) Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics 3:419–428
26. Freeman DJ (2009) Safety and efficacy of panitumumab in the treatment of metastatic colorectal cancer. Clin Med 2009(1):633–645
27. Ganti R et al (2006) Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 19:1213–1220. doi:10.1038/modpathol.3800636
28. Gerber HP, Koehn FE, Abraham RT (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30:625–639. doi:10.1039/c3np20113a
29. Gilabert-Oriol R et al (2013) Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. Mol Pharm 10:4347–4357. doi:10.1021/mp400444q
30. Hristodorov D et al (2013) Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br J Cancer 109:1570–1578. doi:10.1038/bjc.2013.457
31. Hussain AF, Kampmeier F, von Felbert V, Merk HF, Tur MK, Barth S (2011) SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjugate Chem 22:2487–2495. doi:10.1021/bc200304k
32. Jakobovits A, Yang XD, Gallo M, Jia X (2001) Human monoclonal antibodies to epidermal growth factor receptor. US Patent
33. Kamat V et al (2008) Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 7:726–733
34. Kampmeier F, Ribbert M, Nachreiner T, Dembski S, Beaufils F, Brecht A, Barth S (2009) Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjugate Chem 20:1010–1015. doi:10.1021/bc9000257
35. Kampmeier F et al (2010) Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nucl Med Mol Imaging 37:1926–1934. doi:10.1007/s00259-010-1482-5
36. Kim GP, Grothey A (2008) Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics 2:223–228
37. Koefoed K et al (2011) Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. mAbs 3:584–595. doi:10.4161/mabs.3.6.17955
38. Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. AAPS J 8:E532–E551. doi:10.1208/aapsj080363
39. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311. doi:10.1016/j.ccr.2005.03.003
40. Lukianova-Hleb EY, Belyanin A, Kashinath S, Wu X, Lapotko DO (2012) Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells. Biomaterials 33:1821–1826. doi:10.1016/j.biomaterials.2011.11.015
41. Madhumathi J, Verma RS (2012) Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 15:300–309. doi:10.1016/j.mib.2012.05.006
42. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF (2006) EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target 14:215–223. doi:10.1080/10611860600691049
43. Matthey B, Engert A, Klimka A, Diehl V, Barth S (1999) A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene 229:145–153
44. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1s–13s
45. Monnier PP, Vigouroux RJ, Tassew NG (2013) In vivo applications of single chain Fv (variable domain) (scFv) fragments. Antibodies 2:193–208. doi:10.3390/antib2020193
46. Muller KM, Arndt KM, Strittmatter W, Pluckthun A (1998) The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 422:259–264
47. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M (1987) Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252:549–560
48. Nabholtz JM et al (2012) P3-14-01: panitumumab in combination with FEC 100 (5-fluorouracile, epirubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple negative breast cancer (TNBC): final results of a multicentre neoadjuvant pilot phase II study. Cancer Res 71:P3-14-01–P13-14-01. doi:10.1158/0008-5472.sabcs11-p3-14-01
49. Nachreiner T, Kampmeier F, Thepen T, Fischer R, Barth S, Stocker M (2008) Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J Neuroimmunol 195:28–35. doi:10.1016/j.jneuroim.2008.01.001
50. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15
51. Niesen J et al (2014) In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1884-z
52. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. mAbs 6:34–45. doi:10.4161/mabs.27022
53. Pardo A, Stocker M, Kampmeier F, Melmer G, Fischer R, Thepen T, Barth S (2012) In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother (CII) 61:1617–1626. doi:10.1007/s00262-012-1219-3
54. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007) Immunotoxin treatment of cancer. Annu Rev Med. doi:10.1146/annurev.med.58.070605.115320
55. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M (2010) Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70:588–597. doi:10.1158/0008-5472.CAN-09-1417
56. Pines G, Kostler WJ, Yarden Y (2010) Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 584:2699–2706. doi:10.1016/j.febslet.2010.04.019
57. Reichert JM (2014) Antibodies to watch in 2014: mid-year update. MAbs 6(4):799–802. doi:10.4161/mabs.29282
58. Ricci C et al (2000) Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer 87:29–36
59. Sandvig K, van Deurs B (2005) Delivery into cells: lessons learned from plant and bacterial toxins. Gene Ther 12:865–872. doi:10.1038/sj.gt.3302525
60. Sasaki T, Hiroki K, Yamashita Y (2013) The role of epidermal growth factor receptor in cancer metastasis and microenvironment. BioMed Res Int 2013:546318. doi:10.1155/2013/546318
61. Schiffer S et al (2013) Species-dependent functionality of the human cytolytic fusion proteins granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages. Antibodies 2:9–18. doi:10.3390/antib2010009
62. Schlessinger J Givol D, Bellot F, Kris R, Ricca G, Cheadle C, South V (2001) Monoclonal antibodies specific to human epidermal growth factor receptor an therapeutic methods employing same. US Patent
63. Schmidt M, Vakalopoulou E, Schneider DW, Wels W (1997) Construction and functional characterization of scFv(14E1)-ETA—a novel, highly potent antibody-toxin specific for the EGF receptor. Br J Cancer 75:1575–1584
64. Schneider MR, Yarden Y (2014) Structure and function of epigen, the last EGFR ligand. Semin Cell Dev Biol. doi:10.1016/j.semcdb.2013.12.011
65. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159. doi:10.1038/nrd1957
66. Schwenkert M et al (2008) A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res 18:73–84. doi:10.1097/CMR.0b013e3282f7c8f9
67. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287. doi:10.1038/nrc3236
68. Shim H (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med 43:539–549. doi:10.3858/emm.2011.43.10.063
69. Singh R, Samant U, Hyland S, Chaudhari PR, Wels WS, Bandyopadhyay D (2007) Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 6:562–569. doi:10.1158/1535-7163.MCT-06-0604
70. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192–1198. doi:10.1126/science.1241145
71. Stahnke B et al (2008) Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7:2924–2932. doi:10.1158/1535-7163.MCT-08-0554
72. Stein C et al (2010) Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 148:879–889. doi:10.1111/j.1365-2141.2009.08033.x
73. Stocker M, Tur MK, Sasse S, Krussmann A, Barth S, Engert A (2003) Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 28:211–219
74. Tebbutt N, Pedersen MW, Johns TG (2013) Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 13:663–673. doi:10.1038/nrc3559
75. Thorpe SJ, Turner C, Heath A, Feavers I, Vatn I, Natvig JB, Thompson KM (2003) Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol 57:85–92
76. Tur MK et al (2003) Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 63:8414–8419
77. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, Binder M (2012) Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia (New York, NY) 14:1023–1031
78. von Minckwitz G et al (2005) Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res (BCR) 7:R617–R626. doi:10.1186/bcr1264
79. Weidle UH, Georges G, Brinkmann U (2012) Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon. Cancer Genomics Proteomics 9:119–133
80. Weldon JE, Pastan I (2011) A guide to taming a toxin–recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278:4683–4700. doi:10.1111/j.1742-4658.2011.08182.x
81. Wilkins DK, Mayer A (2006) Development of antibodies for cancer therapy. Exp Opin Biol Therapy 6:787–796. doi:10.1517/14712598.6.8.787
82. Wolf P, Gierschner D, Buhler P, Wetterauer U, Elsasser-Beile U (2006) A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother (CII) 55:1367–1373. doi:10.1007/s00262-006-0131-0
83. Wolf P et al (2010) Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J Immunother (Hagerstown, Md: 1997). doi:10.1097/CJI.0b013e3181c5495c
84. Yewale C, Baradia D, Vhora I, Patil S, Misra A (2013) Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34:8690–8707. doi:10.1016/j.biomaterials.2013.07.100